CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Anaplastic thyroid cancer (ATC) is the most aggressive and deadly form of thyroid cancer.
• Identifying effective therapeutic targets is crucial for improving patient survival rates.

Purpose of the Study:

• To explore essential biomarkers for anaplastic thyroid cancer (ATC).
• To establish a gene-targeting therapeutic platform using CRISPR/Cas9 and lentivirus delivery in ATC cells.

Main Methods:

• Analysis of gene expression datasets from CCLE (1036 cancers) and TCGA (8215 tumors) to identify overexpressed genes.
• CRISPR/Cas9 genomic editing system with lentivirus delivery to target EGFR in ATC cells.
• Assessment of afatinib, an FDA-approved EGFR-targeting tyrosine kinase inhibitor (TKI), in an ATC cell line (SW579).

Main Results:

• Epidermal growth factor receptor (EGFR) was found to be significantly overexpressed in thyroid cancers compared to other cancer types.
• CRISPR/Cas9-mediated EGFR targeting in ATC cells led to significant gene and protein expression disruptions, cell cycle arrest, growth inhibition, and suppressed metastasis.
• Afatinib demonstrated potent anticancer activity, including cancer cell death, growth inhibition, and cell cycle arrest, in EGFR-expressing ATC cells.
• Off-target effects of EGFR sgRNAs were minimal, with no detectable genomic editing in candidate off-target genes.

Conclusions:

• EGFR is a critical therapeutic target for anaplastic thyroid cancer.
• CRISPR/Cas9 gene editing and EGFR-targeted therapy (like afatinib) show significant potential for treating ATC.
• These findings provide promising translational strategies to improve survival rates for ATC patients.